Do children’s upper respiratory tract infections benefit from probiotics? by Susanna Esposito et al.
DEBATE Open Access
Do children’s upper respiratory tract infections
benefit from probiotics?
Susanna Esposito1*, Donato Rigante2 and Nicola Principi1
Abstract
Background: The microbiota of the gastrointestinal tract have profound influence at multiple levels, even on the
development and maintenance of lung immunity and inflammation. Aim of this review is to evaluate the current
knowledge about the specific impact on children’s respiratory tract infections from probiotics, live microbes with
the power to modify intestinal microbial populations and exert subsequent benefits for the host.
Discussion: The role of probiotics in gastrointestinal and allergic diseases has been largely assessed, but the
number of studies performed so far in the field of respiratory tract infections is small, though some data show that
probiotic administration might display clinical advantages. Probiotic strain identity and host genetic differences may
account for differential modulation of immune responses by probiotics. Current laboratory and clinical data
regarding the possibility of the role of probiotics on preventing the development of respiratory tract infections are
contradictory, and are somewhat insufficient to recommend strongly their routine use. Further study of
gastrointestinal-respiratory interactions is likely to yield important insights into the pathogenesis of different
pulmonary diseases, and improve our knowledge in the prophylactic role of probiotics in children affected by
recurrent upper respiratory tract infections.
Summary: A better understanding of the effects of different probiotic strains and a deeper insight into their
mechanisms of action are needed for the validation of specific strains carrying a potential to modify the frequency
and severity of RTIs in infants and children. No data have been collected in pediatric patients with chronic
underlying diseases, and yet there are no published data concerning treatment of RTIs with probiotics. The very
few studies published so far do not indicate which micro-organism or administration regimen might exert beneficial
effects as a prevention tool of RTIs both in healthy children and in those with recurrent RTIs. Further research to
establish the role of probiotics in the treatment and prevention of RTIs, including those involving the lower
respiratory tract, are required and should also clarify if any susceptible subgroups of respiratory diseases exist, and
how these subgroups benefit from supplementation with certain probiotic strains.
Keywords: Acute otitis media, Children, Prevention, Probiotics, Respiratory tract infection, Upper respiratory tract
infections
Background
Understanding the microbiome of the airways in normal
subjects is an essential step in overturning our way of
thinking to respiratory medicine, as changes in this micro-
environment could influence the nosography of upper and
lower airways infections and even other clinical outcomes,
such as complications after lung surgery. The importance
of the gastrointestinal tract microbiota in the generation
of mucosal immune responses and mucosal tolerance has
been largely documented also in allergic patients [1-3],
but its interaction with the respiratory pathology is still far
to be elucidated.
Oral probiotics are non-pathogenic live microbes that
when delivered in sufficient quantity can promote health.
The most widely studied probiotics are of 2 genera: Lacto-
bacillus and Bifidobacterium; non-viable microbes have
less immunological activity and can be rarely associated
* Correspondence: susanna.esposito@unimi.it
1Pediatric Highly Intensive Care Unit, Department of Pathophysiology and
Transplantation, Università degli Studi di Milano, Fondazione IRCCS Ca’
Granda Ospedale Maggiore Policlinico, Via Commenda no. 9, Milan 20122,
Italy
Full list of author information is available at the end of the article
© 2014 Esposito et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Esposito et al. BMC Infectious Diseases 2014, 14:194
http://www.biomedcentral.com/1471-2334/14/194
with adverse effects, such as gastrointestinal symptoms or
diarrhea [4]. A range of studies have advocated a role for
probiotics in the prevention and treatment of a wide range
of disorders, and different micro-organisms administered
by means of a nasal or oral spray that are classic airway
commensals have been recently included in the probiotic
family, with the aim of preventing ear, nose and throat
diseases. Albeit with large differences from one micro-
organism to another, it is now established that probiotics
can produce antimicrobial products capable of elimina-
ting bacterial pathogens [5], blocking toxin-mediated re-
sponses [6], interfering with bacteria that are pathogenic
for nutrients and adhesion sites and limiting their pre-
sence and virulence [7], and modulating systemic immune
responses by enhancing humoral and cellular immunity
[8]. Interestingly, probiotics administration seems to be ef-
fective also in the management of food allergy symptoms
but has no effect on the prevention of sensitization [9].
Another major potential benefit of probiotics has been
suggested in patients with asthma [9]. Consequently, pro-
biotics have been extensively used in the area of infectious
and immune-mediated diseases. Most of the data regard-
ing probiotic use in children have been collected in studies
for prevention or treatment of gastrointestinal disorders,
such as infectious and antibiotic-associated diarrhea, tra-
vellers’ diarrhea, necrotizing enterocolitis, and Helicobac-
ter pylori infection [10-12], although a number of recent
studies have also investigated the relationship with atopic
diseases [2,3,9,13].
Comparative evaluations have shown that not all pro-
biotics have the same biological activity, but each has
specific peculiarities in terms of mechanism of action
and efficacy. Routine use of probiotics as an additive
therapy in subjects with gastrointestinal or atopic dis-
eases is very frequent in the everyday clinical practice,
but their administration in children with respiratory
tract infections (RTIs) has been poorly studied and evi-
dences about this topic are still insufficient [13]. Main
goal of this review is to evaluate the actual knowledge
on probiotics in pediatric RTIs and verify which critical
points if resolved might contribute to spread their use in
infants and children with respiratory problems.
Discussion
Respiratory tract infections and probiotics:
a misunderstood relationship
There are no data regarding the use of ingested probio-
tics to treat RTIs; the only studies available are limited
to prevention and are mainly related to the field of
upper respiratory tract infections (URTIs). A recent
Cochrane meta-analysis of 10 clinical trials involving a
total of 3,451 infants, children and adults, found that
probiotics were more beneficial than placebo in terms of
infection prevention, and reduced the rate of acute URTI
and frequency of antibiotic use, but did not decrease the
duration of each single episode [14]. The results of the 7
trials involving only infants and children were likewise
similar [15-21]. Table 1 summarises the main character-
istics of these studies and their conclusions, suggesting
that probiotic administration could be a valuable ap-
proach to preventing URTIs in children, mostly those
with a history of very frequent recurrences. One of the
most interesting study has been published by Hojsak
et al. who showed that children treated with Lacto-
bacillus rhamonosus GG compared with those who re-
ceived the placebo had a significantly reduced risk for
gastrointestinal infections (relative risk [RR]: 0.40 [95%
confidence interval (CI): 0.25-0.70]; number needed to
treat: 15 [95% CI: 9-34]), respiratory tract infections
(RR: 0.38 [95% CI: 0.18-0.85]; number needed to treat:
30 [95% CI: 16-159]), vomiting episodes (RR: 0.5
[95% CI: 0.3-0.9]), diarrheal episodes (RR: 0.24 [95% CI:
0.10-0.50]), episodes of gastrointestinal infections that
lasted >2 days (RR: 0.40 [95% CI: 0.25-0.70]), and epi-
sodes of respiratory tract infections that lasted >3 days
(RR: 0.4 [95% CI: 0.2-0.9]); groups did not differ in
hospitalization duration [17]. Moreover, Rautava et al.
compared infant formula supplemented with the probio-
tics Lactobacillus rhamnosus GG and Bifidobacterium
lactis BB-12 or placebo administered daily until the age
of 12 months and showed that during the first 7 months
of life 7 out of 32 (22%) infants receiving probiotics and
20 out of 40 (50%) infants receiving placebo experienced
acute otitis media (AOM; RR 0.44 [95% CI: 0.21-0.90];
p = 0.014) and antibiotics were prescribed for 10 out of
32 (31%) infants receiving probiotics and 24 out of 40
(60%) infants receiving placebo (RR 0.52 [95% CI: 0.29-
0.92]; p = 0.015) [20]. During the first year of life, 9 out
of 32 (28%) infants receiving probiotics and 22 out of 40
(55%) infants receiving placebo encountered recurrent
respiratory infections (RR 0.51 [95% CI: 0.27-0.95];
p = 0.022) [21]. These data suggested that probiotics may
offer a safe means of reducing the risk of early AOM
and antibiotic use and the risk of recurrent respiratory
infections during the first year of life. However, many ex-
perts have criticized these observations [22], as the
meta-analysis included trials with different inclusion
and exclusion criteria, different primary and secondary
outcomes, different diagnostic criteria, and different
follow-up periods. Furthermore, they used different
probiotics (5 of the 7 studies used Lactobacillus rhamno-
sus GG alone or in combination with other probiotics,
and 2 Lactobacillus casei combined with other micro-
organisms) at various doses and for different times. Con-
sequently, no definite conclusions could be drawn. In
our opinion, although in vitro and experimental data
suggest that probiotics have some effects, it is not
known which is the most effective, which dose and
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Table 1 Clinical trials of probiotics and their use in the prevention of pediatric upper respiratory tract infections (URTIs)
Author, year of publication, country Age range No. of subjects Types of probiotic Main results
Caceres et al. [15], 2010, Chile 1-5 years 398 (203 T, 195 P) Milk-based product, L. rhamnosus HN001, about
108 CFUs/mL
Non-significant reduction of the number of URTIs per
child between groups
Hatakka et al. [16], 2007, Finland 10 months-6 years 309 (155 T, 154 P) Gelatine capsule, a combination of L. rhamnosus
GG, ATCC 53103, L. rhamnosus LC 705,
Bifidobacterium breve PP, Propionibacterium
freudenreichi spp. shermanii IS, 8–9 × 109 CFUs
of each strain/capsule
Probiotics did not prevent the occurrence of acute
otitis media or the nasopharyngeal carriage of otitis
pathogens in otitis-prone children; a reduction in the
frequency of recurrent respiratory infections was also
noted
Hojsak et al. [17], 2010, Croatia 13 months-7 years 281 (139 T, 142 P) Fermented milk product, L. rhamnosus strain
GG, 109 CFUs
L. rhamnosus GG decreased the risk of nosocomial
gastro-intestinal and respiratory tract infections in
pediatric facilities
Hojsak et al. [18], 2010, Croatia >12 months 742 (376 T, 366 P) Fermented milk product, L. rhamnosus strain
GG, 109 CFUs
L. rhamnosus GG decreased the risk of upper respiratory
tract infections in children attending day care centres
Merenstein et al. [19], 2010, USA 3-6 years 638 (314 T, 324 P) L. casei DN-114 001/CNCM I-1518 (also called
L. paracasei subsp. paracasei in the current
nomen-clature), 1 × 108 CFUs/g, Streptococcus
thermophilus and L. bulgaricus, 10 × 7 CFUs/g
Probiotics reduced the overall incidence of common
infectious diseases
Rautava et al. [20], Finland 0-2 months 81 (38 T, 43 P) L. rhamnosus and B. lactis BB-12, 1 × 1010 CFUs Probiotics reduced the risk of early acute otitis media,
antibiotic use and recurrent respiratory infections
during the first year of life
Rio et al. [21], 2009, Argentina 6-24 months 100 (50 T, 50 P) Fermented milk products, L. acidophilus and
L. casei, 107 to 108/mL
Live Lactobacillus supplement suppressed pneumonia
and decreased bronchitis in both undernourished and
normal subjects



















which duration of administration might lead to the best
results, or which type of URTI is the most susceptible to
probiotic use.
The role of different probiotics has been evaluated in
two works by Weizman et al. [23] and Agustina et al.
[24]. The first was a double-blind placebo-controlled
randomised trial of a formula supplemented with Bifido-
bacterium lactis (BB-12), or Lactobacillus reuteri 55730,
or no probiotics administered for 12 weeks to healthy
term-infants aged 4–10 months at 14 child care centres in
Israel [23]. In comparison with controls, children treated
with BB-12 or Lactobacillus reuteri experienced signifi-
cantly fewer episodes of fever and diarrhea, although there
were no between-group differences in the overall inci-
dence of RTIs. The second was a 6-month double-blind
placebo-controlled study of 494 healthy children aged
1–6 years, who received low-lactose milk with a low-
calcium content (LC 50 mg/day; n = 124), regular calcium
content (RC 440 mg/day; n = 126), RC with 5.108 colony-
forming units (CFUs) per day of Lactobacillus casei
CRL431 (n = 120), or RC with 5.108 CFUs per day of
Lactobacillus reuteri DSM17938 (n = 124): it was found
that the incidence of diarrhea episodes was significantly
lower in children receiving Lactobacillus reuteri DSM17938
than in any other group, whereas Lactobacillus casei had
no effect. In addition, none of these treatments modified
the incidence of RTIs [24].
Different probiotic bacteria have been associated with
variable stimuli to the human innate and adaptive im-
mune system and co-mediate metabolic and immune
homeostasis, with different levels of success: probiotic
strain identity and host genetic differences may account
for differential modulation of immune responses by pro-
biotics [25]. Villena et al. used an experimental model of
lung inflammation based on the administration of the arti-
ficial viral pathogen-associated molecular pattern poly
(I:C), in order to mimic the pro-inflammatory and physio-
pathological consequences of RNA viral infections in the
lung, and evaluated changes in mouse immunity after oral
administration of Lactobacillus rhamnosus CRL 1505 and
CRL 1506. The authors found that CRL 1506 had no ef-
fect, whereas CRL 1505 increased bronchoalveolar lavage
concentrations of interleukin(IL)-6, interferon(IFN)-γ and
IL-10, and the number of pulmonary CD3 + CD4 + IFN-
γ + T cells; the preventive effects on the respiratory airway
immunity induced by CRL 1505, suggested that, if the tar-
get of probiotic administration is to prevent recurrent
URTIs, an appropriate strain of Lactobacillus rhamnosus
should be selected [26].
Finally, all actual available data show that the com-
bination of different micro-organisms does not always
induce more favourable immune modulation, and can
lead to negative results on the other hand, underlining
the need for specific studies of different probiotic
combinations. Hatakka et al. performed a 24-week ran-
domized double-blind placebo-controlled interventional
study, in which 309 children aged between 10 months and
6 years took one probiotic capsule containing several
micro-organisms (Lactobacillus rhamnosus GG, ATCC
53103, Lactobacillus rhamnosus LC 705, Bifidobacterium
breve 99 and Propionibacterium freudenreichii spp. sher-
manii JS) (n = 155) or placebo (n = 154) once a day [22]:
the results of this observation revealed that probiotics did
not decrease occurrence, recurrence, or duration of AOM
episodes in the population studied (probiotic vs placebo
respectively: 72% vs 65%, p > 0.05; 18% vs 17%, p > 0.05;
5.6 vs 6.0 days, p > 0.05).
Administration of probiotics via nasal or oral spray
An alternative to the use of ingested probiotics is to ad-
minister airway commensals by means of a nasal or oral
spray. This approach is based on the finding that there is
a dynamic and antagonistic interaction in the nasophar-
ynx among different colonising organisms, whose mani-
fold infectious potential affects their life cycle, changes
the microenvironment, and alters their invasiveness or
ability to affect the overall health of the host [27]. Reco-
lonisation with commensal bacteria can reduce the levels
of real pathogens and consequently limit the number of
new respiratory infections. The first studies were carried
out using α Streptococcus, showing that a 10-day admi-
nistration after standard antibiotic therapy reduced the
recurrence rates of both pharyngotonsillitis [28] and
AOM [29]. However, this probiotic approach was sub-
sequently dropped, because of the pathogenicity of α
Streptococcus, and has only recently been reconsidered
using different poorly-infecting bacterial strains capable
of producing bacteriocidins.
In vitro studies have found that both Lactobacillus hel-
veticus MIMLh5 and Streptococcus salivarius ST3 can effi-
caciously adhere to pharyngeal epithelial cells, antagonize
Streptococcus pyogenes, and modulate host innate im-
munity, mainly by stimulating the expression of the pro-
inflammatory cytokine tumour necrosis factor-alpha [30].
Santagati et al. have identified 13 α-hemolytic Strep-
tococci bacteriocidin-producers capable of inhibiting
different Gram-positive pathogens, and found that Strep-
tococcus salivarius 24SMB does not possess any virulence
factor and is a strong producer of bacteriocidins against
Streptococcus pneumoniae, the most common respiratory
bacterial pathogen [31]. However, although these studies
provide hopeful indications for the preparation of probio-
tics in preventing URTIs, human clinical trials have not
yet been performed.
Safety and tolerability concerns for probiotics
Lactobacilli and bifidobacteria have generally been
regarded as safe, although there are significant safety
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concerns in particular populations [32]. A host of experi-
mental data and case reports certify that probiotics might
increase the risk of sepsis. Table 2 lists the categories of
patients at risk for a probiotic-induced sepsis. The colo-
nisation of neonatal athymic mice with human isolates
of Lactobacillus reuteri, Lactobacillus acidofilus, Bifido-
bacterium animalis, or Lactobacillus rhamnosus GG can
bring about a lethal sepsis [33], suggesting that immune
deficiency in the first period of life might increase the risk
of probiotic-related sepsis. Furthermore, a number of pub-
lications have reported the development of sepsis in adult
and pediatric patients receiving probiotic supplements.
The most frequently isolated micro-organisms have been
Lactobacillus rhamnosus GG and Saccharomyces bulardii,
although their hypothetical greater invasiveness remains
to be established. Interestingly, in most of these cases,
pulse-field gel electrophoresis of chromosomal DNA re-
striction fragments showed that the bacteremic and pro-
biotic strains were indistinguishable, confirming a direct
relationship between the development of infection and
probiotics [34,35]. All cases of probiotic-induced sepsis
(including those occurring in children) were diagnosed in
immunocompromised patients or subjects with a severe
underlying disease. Prematurity can be considered as an
additional risk factor for the development of probiotic-
induced sepsis, even if probiotic administration has been
found effective in reducing the risk of infections in neo-
nates with very low birth weight [36].
Another concern associated with use of probiotics is the
risk of immune deviation or excessive immune stimula-
tion. Intestinal microbiota play a crucial role in normal
immune development, and it cannot be excluded that ma-
nipulations designed to alter microbiota by administering
probiotics may have significant and persistent immune-
modulatory effects. This may be particularly relevant
during pregnancy or in the first months of life, because
significant abnormalities in microbiota during the first
phases of immune system development might lead to
major changes in immune responses. It is well known that
T cell responses show a bias towards a Th2-phenotype
during pregnancy, essential for maintaining fetal viability
[37]. As Lactobacillus spp. suppresses Th2-cytokine re-
sponses in vitro, and has been found to increase the pro-
duction of the Th1-cytokine IFN-γ in some studies, it was
initially thought that a probiotic administration might
cause fetal loss [38]. Fortunately, there is still no direct evi-
dence of this risk, although further investigation in this
field is highly needed [32].
The effect of probiotic administration during preg-
nancy on infants has been studied in different clinical
trials [39-43]. Aim of these studies was to evaluate
whether probiotics reduce the risk of developing atopic
disease, particularly in children with at least one family
member affected by atopic disease. Results were con-
flicting, and one of the studies clearly showed that pro-
biotics had an unexpected negative effect [40]. This was
a study in which 94 mothers received Lactobacillus GG
(American Type Culture Collection 53103; 5 × 109 CFUs)
or placebo twice daily starting 4–6 weeks before ex-
pected delivery and continuing after the first 6 post-
natal months. Children were monitored for 2 years, and
it was found that recurrent (i.e. ≥5) episodes of wheezing
bronchitis were more frequent in the Lactobacillus
rhamnosus GG group (26%; n = 13) than in the control
group (9.1%; n = 4), suggesting that the maternal admi-
nistration of this probiotic may be associated with an
increased risk of infectious bronchitis with wheezing in
infants for a long time after birth. As no further reports
suggesting similar conclusions have been published, it is
not possible to establish whether the association was for-
tuitous or an increased risk of infections exists when the
probiotic is given to pregnant women.
Summary
A better understanding of the effects of different pro-
biotic strains and a deeper insight into their mechanisms
of action are needed for the validation of specific strains
carrying a potential to modify the frequency and severity
of RTIs in infants and children. No data have been
collected in pediatric patients with chronic underlying
diseases, and yet there are no published data concerning
treatment of URTIs with probiotics as well as the possi-
bility to reduce the severity of symptoms. The very few
studies published so far do not indicate which micro-
organism or administration regimen might exert benefi-
cial effects as a prevention tool of RTIs both in healthy
children and in those with recurrent URTIs. Further
research to establish the role of probiotics in the treat-
ment and prevention of RTIs, including those involving
the lower respiratory tract, are required and should
also clarify if any susceptible subgroups of respiratory
Table 2 Patients showing high or low risk for a
probiotic-induced sepsis
Type of risk Patients
High Immunocompromised patients
Premature neonates
Low Patients with a central venous catheter
Patients receiving probiotics by jejunostomy
Patients concomitantly receiving broad spectrum
antibiotics to which the probiotic is resistant
Patients receiving probiotics with high mucosal
adhesion properties or showing an established
pathogenicity
Patients with cardiac valvular disease (for Lactobacillus
probiotics only)
The presence in the same patients of a single major or more than one minor
risk factor dictates caution when using probiotics.
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diseases exist, and how these subgroups benefit from sup-
plementation with certain probiotic strains. Therefore, re-
search activities are focusing currently upon identification
of specific probiotic strains with immunomodulatory po-
tential and upon how dietary content interacts with them.
Selection of the most beneficial probiotic strain, the dose
and timing of supplementation still need to be determined
and further study of gastrointestinal-respiratory interac-
tions will yield important insights into the pathogenesis of
pulmonary diseases, including cystic fibrosis, respiratory
disease of the newborn, and asthma, and improve our
knowledge in the prophylactic role of probiotics in
children affected by recurrent upper respiratory tract
infections.
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